News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Welichem Biotech Inc. (WBI.V) Ends Effort To Re-Acquire China Rights To Psoriasis Treatment



7/28/2014 8:03:28 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

In a complicated deal, Welichem Biotech of Canada ended its attempt to buy back China rights to a topical psoriasis treatment from Shenzhen Celestial Pharma and Beijing Wenfeng Tianji Pharma. The company explained that China authorities have not given their approval to the deal, and the Board decided approval was not likely. Welichem originally sold China rights to WBI-1001 in September 2004 in exchange for a $1.5 million investment by Celestial in Welichem.

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES